Blair William & Co. IL Acquires 44,610 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Blair William & Co. IL lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 32.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 180,564 shares of the company’s stock after buying an additional 44,610 shares during the quarter. Blair William & Co. IL owned about 0.54% of TransMedics Group worth $11,258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in TMDX. Vanguard Group Inc. grew its holdings in TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock worth $226,700,000 after purchasing an additional 40,860 shares during the period. Geode Capital Management LLC raised its stake in TransMedics Group by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after buying an additional 10,106 shares during the last quarter. Emerald Advisers LLC lifted its holdings in shares of TransMedics Group by 146.3% during the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after buying an additional 220,804 shares during the period. Vaughan Nelson Investment Management L.P. grew its holdings in shares of TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after acquiring an additional 32,605 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in TransMedics Group by 9.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 297,433 shares of the company’s stock valued at $18,545,000 after acquiring an additional 25,739 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Down 2.6 %

NASDAQ TMDX opened at $68.58 on Friday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock has a market cap of $2.31 billion, a PE ratio of 72.96 and a beta of 2.12. The stock’s 50 day moving average is $69.11 and its 200 day moving average is $88.41.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday. Canaccord Genuity Group restated a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Robert W. Baird lowered their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.